PharmiWeb.com - Global Pharma News & Resources
16-Aug-2018

FIT Biotech Oy: Chairman of the board on leave of absence

FIT Biotech Oy                                                            

Company release 16.8.2018 at 04:00 PM EET

Chairman of the board on leave of absence

FIT Biotech's ("FIT Biotech", FITBIO: FN Finland) chairman of the board, Rabbe Slätis, has announced an indefinite leave of absence from the position of chairman of the board, due to medical reasons. Dr. Chitra Bharucha has today 16.8.2018 been nominated as the vice-chairman of the board. She will be responsible for the duties of chairman of the board during Slätis' absence. Rabbe Slätis will still continue as a member of the board.

FIT Biotech's board members are chairman of the board Rabbe Slätis, vice-chairman of the board Chitra Bharucha, Eero Rautalahti, Anne-Maria Salonius and Juhani Pitkäkoski.  

FIT Biotech OY
Board of Directors

For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
E-mail: erkki.pekkarinen@fitbiotech.com

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
Nasdaq Helsinki
Principal media



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: FIT Biotech Oy via GlobeNewswire
HUG#2211081

Editor Details

Last Updated: 17-Aug-2018